Compare iShares iBoxx $ High Yield Corporate Bond ETF (HYG) vs Zimmer Biomet Holdings Inc (ZBH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares iBoxx $ High Yield Corporate Bond ETF vs Zimmer Biomet Holdings Inc — how do they compare? iShares iBoxx $ High Yield Corporate Bond ETF trades at $77.23 (market cap $17.89B), while Zimmer Biomet Holdings Inc trades at $89.14 (market cap $16.95B). The key difference: iShares iBoxx $ High Yield Corporate Bond ETF and Zimmer Biomet Holdings Inc are close in size by market cap, and Zimmer Biomet Holdings Inc pays a 1.08% dividend while iShares iBoxx $ High Yield Corporate Bond ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold iShares iBoxx $ High Yield Corporate Bond ETF for 60 Days and Zimmer Biomet Holdings Inc for 89 Days on average.
| HYG | ZBH | |
|---|---|---|
Market Cap | $17.89B | $16.95B |
Volume | 44,866,592 | 2,505,240 |
Sector | Fixed Income | Health |
52-Week High | $81.28 | $103.98 |
52-Week Low | $76.90 | $79.58 |
Typical Hold Time | 60 Days | 89 Days |
Enterprise Value | — | $24.02B |
Dividend Yield | — | 1.08% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
HYG trades at $77.14, down 0.05% on the day, with technical indicators showing a bearish trend as moving averages signal strong selling pressure. The ETF maintains consistent dividend distributions with recent payouts ranging from $0.38 to $0.44. Market sentiment is heavily influenced by the broader bond selloff as Treasury yields reach multi-decade highs, creating headwinds for high-yield corporate bonds.
Current market conditions present challenges for HYG as rising interest rates pressure high-yield bond valuations. The ETF's performance remains tied to Federal Reserve policy and corporate credit conditions, with upside potential limited until bond market volatility subsides. Key risks include further rate hikes and economic slowdown impacting junk bond issuers.
Zimmer Biomet (ZBH) trades at $88.91, up 0.47% today, with a bearish technical signal from moving averages. The company reported Q2 2026 EPS of $2.07, beating estimates, and raised its 2026 outlook. Revenue growth remains steady, with 2025 revenue at $8.23B, though net income margin declined to 8.56%. The stock is supported by a quarterly dividend of $0.24 and a consensus price target of $103.11, suggesting potential upside.
The outlook is mixed: strong fundamentals and analyst optimism contrast with technical weakness. Investment opportunities include consistent earnings beats and dividend income, but risks involve rising debt levels and competitive pressures in the medical technology sector. The stock's current valuation at a P/E of 21.57 appears reasonable if growth continues.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About iShares iBoxx $ High Yield Corporate Bond ETF
HYG is the world's largest high-yield bond ETF, tracking the Markit iBoxx USD Liquid High Yield Index. It provides liquid exposure to non-investment grade corporate debt, with 2026 top holdings including Cloud Software Group and Medline.
Read more on HYG →About Zimmer Biomet Holdings Inc
Zimmer Biomet designs, manufactures, and markets orthopedic reconstructive implants, as well as supplies and surgical equipment for orthopedic surgery. With the acquisitions of Centerpulse in 2003 and Biomet in 2015, Zimmer holds the leading share of the reconstructive market in the United States, Europe, and Japan. Roughly 70% of total revenue is derived from sales of large joints, another quarter comes from extremities, trauma, and related surgical products.
Read more on ZBH →
